STOCK TITAN
  1. Home
  2. Sec-filings
  3. ETON
  4. [144] Eton Pharmaceuticals, Inc. SEC Filing

Eton Pharma (NASDAQ: ETON) insider plans sale after $1.8M May trades

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. (ETON) has an affiliated officer, David Krempa, filing a Rule 144 notice to sell up to 25,000 shares of common stock through Raymond James & Associates, Inc. The planned sale on 08/24/2026 is tied to a stock option exercise for cash.

During the prior three months, Krempa reported sales of 37,524 shares of Eton common stock on 05/26/2026 for $1,180,201.00 and 19,679 shares on 05/27/2026 for $618,569.00. The shares are listed on Nasdaq, and Raymond James is identified as the broker handling the proposed transaction.

Positive

  • None.

Negative

  • None.
Planned shares to be sold 25,000 shares Common stock proposed to be sold by David Krempa under Rule 144
Prior sale on 05/26/2026 37,524 shares for $1,180,201.00 Common stock sold by David Krempa during past three months
Prior sale on 05/27/2026 19,679 shares for $618,569.00 Common stock sold by David Krempa during past three months
Planned transaction date 08/24/2026 Date associated with stock option exercise and proposed sale
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Stock Option Exercise financial
"Common | 08/24/2026 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
attorney-in-fact regulatory
"as attorney-in-fact for David Charles Krempa"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing disclose for ETON?
The filing discloses that officer David Krempa intends to sell up to 25,000 shares of Eton Pharmaceuticals, Inc. common stock under Rule 144, through Raymond James & Associates, Inc., in connection with a stock option exercise for cash dated 08/24/2026.

How many ETON shares has David Krempa sold in the past three months?
Over the past three months, David Krempa reported selling 37,524 shares on 05/26/2026 for $1,180,201.00 and 19,679 shares on 05/27/2026 for $618,569.00, all in Eton Pharmaceuticals, Inc. common stock.

What is the size of the proposed ETON share sale in this Form 144?
The notice covers a proposed sale of up to 25,000 shares of Eton Pharmaceuticals, Inc. common stock. The broker listed is Raymond James & Associates, Inc., and the transaction is associated with a stock option exercise on 08/24/2026.

What type of transaction is associated with the planned ETON share sale?
The planned sale of Eton Pharmaceuticals, Inc. shares is associated with a Stock Option Exercise for cash, with an intended transaction date of 08/24/2026. This is disclosed in the securities-to-be-sold section of the notice.

On which market are ETON shares involved in this Form 144 listed?
The common shares referenced in this Form 144 for Eton Pharmaceuticals, Inc. are listed on Nasdaq, as indicated in the securities information section of the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR